PPPetr Prasil

Petr Prasil

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Petr Prasil has a total of 23 co-authors. Here are the top co-authors by number of shared publications:

  • Pavel Bostik

    Institute of Clinical Microbiology, Faculty of Medicine in Hradec Kralove, Charles University and University Hospital, 50005 Hradec Kralove, Czech Republic

    2 shared publications
  • Barbora Voxova

    Department of Clinical Microbiology, Charles University in Prague, Faculty of Medicine in Hradec Kralove and University Hospital in Hradec Kralove, Sokolska 581, 500 05, Hradec Kralove, Czech Republic

    1 shared publication
  • Helena Žemličková

    Department of Clinical Microbiology, University Hospital and Faculty of Medicine in Hradec Kralove, Charles University, Hradec Kralove, Czech Republic

    1 shared publication
  • Jakub Radocha

    184th Department of Internal Medicine – Hematology, University Hospital Hradec Králové, Faculty of Medicine in Hradec Králové, Charles University, Hradec Králové, Czech Republic

    1 shared publication
  • Josef Scharfen

    Department of Clinical Microbiology, Charles University in Prague, Faculty of Medicine in Hradec Kralove and University Hospital in Hradec Kralove, Sokolska 581, 500 05, Hradec Kralove, Czech Republic

    1 shared publication
  • Katerina Kuncova

    1 shared publication

Latest Publications

  • Open Access

    Comparison of adverse reactions of spiramycin versus pyrimethamine/sulfadiazine treatment of toxoplasmosis in pregnancy: is spiramycin really the drug of choice for unproven infection of the fetus?

    by Petr Prasil, Radek Sleha, Marian Kacerovsky, Pavel Bostik

    Therapeutic regimens for the treatment of toxoplasmosis are not standardized. Treatment strategy mainly at the end of the second and the beginning of the third trimester, especially in cases of negative prenatal diagnosis, is the least uniform. In some situations, the choice of treatment may be ambiguous, and adverse drug reactions of the therapy should be taken into consideration. Adverse drug reactions of anti-toxoplasma therapy with spiramycin (n = 77) versus pyrimethamine/sulfadiazine (n = 35) were compared in 112 pregnant women. Up to 36.6% of women reported adverse reactions to the treatment overall (n = 41). Out of those 38.9% (n = 30) were treated with spiramycin and 31.4% (n = 11) with pyrimethamine/sulfadiazine. Toxic allergic reactions were the only indication for discontinuation of treatment in 8.9% of patients (n = 10), where 9.1% (n = 7) were reported in spiramycin and 8.6% (n = 3) in pyrimethamine/sulfadiazine cohort. Neurotoxic complications (acral paraesthesia) were significantly more frequent during the therapy with spiramycine in 19.5% (n = 15) compared to no cases in pyrimethamine/sulfadiazine group (p = .003). Other adverse drug reactions, such as gastrointestinal discomfort, nephrotoxicity, vaginal discomfort were reported, but the differences between the cohorts were not significant. The superiority of one of the therapeutic regimens was not statistically demonstrated, since the differences in overall toxicity or incidence of toxic allergic reactions between the cohorts were not confirmed (p = .53 and p = 1.00, respectively). However, although the isolated neurotoxicity of spiramycin was the only significant adverse reaction demonstrated in this study, pyrimethamine/sulfadiazine therapy should be preferred, because it is known to be more effective and with limited adverse reactions.


  • EFFECTS OF FLUOROQUINOLONE RESTRICTION IN THE HOSPITAL ON THE DEVELOPMENT OF SENSITIVITY OF SELECTED BACTERIAL PATHOGENS

    by Pavla Paterova, Lenka Ryskova, Miroslav Fajfr, Katerina Kuncova, Katerina Neradova, Kristyna Vaverkova, Lenka Hobzova, Petr Prasil, Stanislav Plisek, Jakub Radocha, et al.

  • Open Access

    Leptospirosis: possibilities of early laboratory and clinical diagnosis

    by Zuzana Cermakova, Petra Kucerova, Zbynek Valenta, Lenka Pliskova, Radka Bolehovska, Petr Prasil, Vladimir Buchta, Josef Scharfen, Pavel Polak, Ota Pavlis, et al.

    This retrospective study aims to identify and describe the problems associated with the laboratory and clinical diagnosis of leptospirosis. A total of 4,813 patients with suspected leptospirosis from an area of the Czech Republic, with a total population of 1.15 million, were examined during the period 2002–2010. Our study included only 855 patients: 545 men (mean age 41.03 ± 19.24) and 310 women (mean age 41.47 ± 20.3) who were examined using microscopic agglutination test (MAT) and a polymerase chain reaction (PCR). All patients and their physicians filled in questionnaires, which included anamnestic data, clinical symptoms and the results of laboratory tests. Out of total suspected, 89 patients (1.85%), tested positive for leptospirosis, of which 50 have been examined only serologically by MAT. Of 855 patients in our study undergoing both PCR and MAT tests, 39 have tested positive for leptospirosis. The most frequent symptom in patients with leptospirosis included fever (91.6%) and headache (69.4%). The correct laboratory diagnosis of leptospirosis depends on biological material being tested before the start of antibiotic treatment, since leptospires are extremely sensitive to antibiotics. Consequently, the PCR results alone may produce a false negative result after 24 hours following treatment with antibiotics.